Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.
As the first cohort of patients are dosed in the Phase II trial, multiple new trial sites are added for the glioblastoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback